雷替曲塞联合多西他赛加奥沙利铂治疗初诊晚期胃癌的临床研究

摘要

Objective:To investigate the clinical efficacy and side effects on raltitrexed combined docetaxel and oxaliplatin in the treatment of advanced gastric cancer.Methods:57 patients with histological diagnosis of advanced gastric cancer without treatment were randomly divided into 2 groups:the treatment group(including 28 patients)with the use of raltitrexed combined docetaxel and oxaliplatin and the control group(including 29 patients)with the use of classical FOLFOX4,and observe and evaluate the curative effect of two groups of treatment and side effects.Result:the treatment group had significantly higher response rate,beter disease control rate,and longer median time to disease progression cornpared with the control(P<0.05).But there was no difference in overal survival between the two(8.3 months vs 7.9 months)(P>0.05).In addition,the treatment group had higher side effects which could be controled.Conclusion:the use of raltitrexed combined docetaxel and oxaliplatin for the treatment of advanced gastric cancer is more beneficial to patients.%目的：探讨雷替曲塞联合多西他赛加奥沙利铂治疗晚期胃癌的临床疗效及其副作用。方法：选取我院57例经病理组织学证实的患者，随机分为2组：治疗组(28例)和对照组(29例)，分别予“雷替曲塞+奥沙利铂+多西他赛”方案和经典的FOLFOX4方案化疗。观察并评价两组治疗方案的疗效及副作用。结果：治疗组的疾病治疗有效率、控制率及中位疾病进展时间均高于对照组，有统计学差异(P<0.05)；但两组中位总生存时间未见明显差异，分别为8.3个月和7.9个月，无统计学差异(P>0.05)。此外，治疗组总的副作用发生率要高于对照组，多在可控制范围内。结论：雷替曲塞联合多西他赛加奥沙利铂治疗晚期胃癌安全有效，值得临床推广应用。